Pharmacological risk factors for amphotericin B nephrotoxicity in children

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 1049-1054

  Goldman, Ran D ^a   Ong, Michael ^a   Wolpin, Jacob ^a   Doyle, John ^b   Parshuram, Christopher ^b   Koren, Gideon ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Amphotericin; Children; Nephrotoxicity; Risk factors

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DIMENHYDRINATE; DIPHENHYDRAMINE; FLUCONAZOLE; FUROSEMIDE; IMMUNOGLOBULIN; LORAZEPAM; MEROPENEM; METHOTREXATE; METRONIDAZOLE; MORPHINE; NIFEDIPINE; NYSTATIN; OMEPRAZOLE; ONDANSETRON; PARACETAMOL; PETHIDINE; PIPERACILLIN; POTASSIUM CHLORIDE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOBRAMYCIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; CANDIDIASIS; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA ANALYSIS; FEMALE; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CREATININE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY DISEASES; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34447624284     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007301799     Document Type: Article

References (29)

1. Sarosi GA Amphotericin B still the 'gold standard' for antifungal therapy. Postgrad Med. 1990 ; 88: 151-165.
2. Gallis HA, Drew RH, Pickard WW Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1995 ; 12: 308-329.
3. Beck-Sague C., Jarvis WR Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993 ; 167: 1247-1251.
4. Wingard JR, Kubilis P., Lee L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999 ; 29: 1402-1407.
5. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol. 2004 ; 26: 421-426.
6. Atkinson AJ Jr, Bennett JE Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978 ; 13: 271-276.
7. Koren G., Lau A., Klein J., et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988 ; 113: 559-563.
8. Starke JR, Mason EO Jr, Kramer WG, Kaplan SL Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987 ; 155: 766-774.
9. Benson JM, Nahata MC Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989 ; 33: 1989-1993.
10. Koren G., Lau A., Kenyon CF, Kroppert D., Klein J. Clinical course and pharmacokinetics following a massive overdose of amphotericin B in a neonate. J Toxicol Clin Toxicol. 1990 ; 28: 371-378.
11. Pathak A., Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis. 1998 ; 26: 334-338.
12. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited: reassessment of toxicity. Am J Med. 1990 ; 88: 22N - 27N.
13. Luber AD, Maa L., Lam M., Guglielmo BJ Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999 ; 43: 267-271.
14. Stein RS, Albridge K., Lenox RK, Ray W., Flexner JM Nephrotoxicity in leukemic patients receiving empirical amphotericin B and aminoglycosides. South Med J. 1988 ; 81: 1095-1099.
15. Harbarth S., Pestotnik SL, Lloyd JF, Burke JP, Samore MH The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med. 2001 ; 111: 528-534.
16. White MH, Anaissie EJ, Kusne S., et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997 ; 24: 635-642.
17. McCormack JP, Jewesson PJ A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992 ; 14: 320-339.
18. Zager RA, Bredl CR, Schimpf BA Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int. 1992 ; 41: 1588-1594.
19. Bell NH, Andriole VT, Sabesin SM, Utz JP On the nephrotoxicity of amphotericin B in man. Am J Med. 1962 ; 33: 64-69.
20. Butler WT, Hill GJ II, Szwed CF, Knight V. Amphotericin B renal toxicity in the dog. J Pharmacol Exp Ther. 1964 ; 143: 47-56.
21. Tolins JP, Raij L. Adverse effect of amphotericin B administration on renal hemodynamics in the rat: neurohumoral mechanisms and influence of calcium channel blockade. J Pharmacol Exp Ther. 1988 ; 245: 594-599.
22. Sabra R., Takahashi K., Branch RA, Badr KF Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: a micropuncture study. J Pharmacol Exp Ther. 1990 ; 253: 34-37.
23. Gerkens JF, Branch RA The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther. 1980 ; 214: 306-311.
24. Sabra R., Branch RA Amphotericin B nephrotoxicity. Drug Saf. 1990 ; 5: 94-108.
25. Varlam DE, Siddiq MM, Parton LA, Russmann H. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother. 2001 ; 45: 679-685.
26. Fisher MA, Talbot GH, Maislin G., McKeon BP, Tynan KP, Strom BL Risk factors for amphotericin B-associated nephrotoxicity. Am J Med. 1989 ; 87: 547-552.
27. Kennedy MS, Deeg HJ, Siegel M., Crowley JJ, Storb R., Thomas ED Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983 ; 35: 211-215.
28. Ringden O., Andstrom E., Remberger M., Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant. 1994 ; 14: S10 - S14.
29. Lomaestro BM Fluoroquinolone-induced renal failure. Drug Saf. 2000 ; 22: 479-485.